Corpus overview


MeSH Disease

Human Phenotype

Fever (56)

Cough (43)

Pneumonia (15)

Fatigue (15)

Dyspnea (14)


    displaying 11 - 20 records in total 56
    records per page

    Recovery of moderate COVID-19 disease in a liver MESHD transplant recipient on continued immunosuppression

    Authors: Victor Dahl Mathiasen; Stine Karlsen; Peter Ott; Søren Jensen-Fangel; Steffen Leth

    doi:10.21203/ Date: 2020-06-29 Source: ResearchSquare

    BackgroundThe global outbreak of severe acute respiratory syndrome MESHD coronavirus 2 has had an enormous impact on the world. It remains unclear to what extent liver transplant recipients should be considered at a higher risk of severe disease MESHD due to the limited data available.Case presentationWe describe a moderate course of COVID-19 in a patient who underwent a liver transplant two years earlier due to Budd-Chiari syndrome MESHD Budd-Chiari syndrome HP. She presented with malaise, headache MESHD headache HP, dry cough MESHD cough HP and fever MESHD fever HP for four days. Immunosuppressive therapy with tacrolimus and mycophenolate mofetil was continued throughout the course of infection MESHD, oxygen therapy was given for a single night and the patient gradually recovered with supportive care only.ConclusionsWith this case report, we demonstrate that liver transplantation and immunosuppression is not necessarily associated with severe COVID-19 disease MESHD and emphasize that more information on this matter is urgently required. Withdrawal of immunosuppressive therapy could be associated with a higher mortality.

    Seroprevalence SERO against COVID-19 and follow-up of suspected cases in primary TRANS health care in Spain

    Authors: Carlos Brotons; Jordi Serrano; Diana Fernandez; Carlos Garcia-Ramos; Begona Ichazo; Jeannine Lemaire; Patricia Montenegro; Irene Moral; Ricky Perez- Wienese; Marc Pitarch; Mireia Puig; Maria Teresa Vilella; Jaume Sellares

    doi:10.1101/2020.06.13.20130575 Date: 2020-06-16 Source: medRxiv

    Background During the coronavirus disease MESHD 2019 (COVID-19) pandemic little information has been available about patients with mild or moderate symptoms attended and followed in the primary care setting, most of whom had an unknown status for the severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) infection MESHD. Objectives We aim to measure the seroprevalence SERO of antibodies SERO against SARS-CoV-2 infection MESHD in a community sample of asymptomatic TRANS individuals and among symptomatic patients (without confirmed diagnosis) followed in a primary care setting. As a secondary objective, we estimated the proportions of symptomatic patients seeing at an emergency MESHD department (ED), hospitalized or dying, and identified the most important clinical symptoms associated with a positive infection MESHD. Methods From April 21 to April 24 2020, we selected a random sample of 600 individuals stratified by age groups TRANS, from a total population of 19,899 individuals from a community area in Barcelona (study population 1). From April 29 to May 5 2020, we also invited all the patients that had been followed by general practitioners (GPs) (study population 2). We used for both populations COVID-19 Rapid lateral flow immunoassay SERO which qualitatively assesses the presence of patient-generated IgG and IgM in approximately 10-15 minutes. The prevalence SERO (95% confidence intervals [CI]) of infection MESHD (past and current) was defined as the proportion of individuals with antibody SERO seropositivity. Odds ratios (ORs) for a positive test result were estimated using logistic regression analysis. Results Three hundred and eleven asymptomatic TRANS individuals from the randomly selected sample accepted to participate in the study. The overall mean age TRANS was 43.7 years (SD 21.79, range 1-94) and 55% were women. Seventeen individuals were seropositive for IgM and/or IgG, resulting an overall prevalence SERO of 5,47% (95% CI, 3.44-8.58). Six-hundred and thirty-four symptomatic patients were followed by GPs. The overall mean age TRANS was 46.97 years (SD 20.05, range 0-92) and 57.73% were women. Of these, 244 patients (38.49%) were seropositive for IgM and/or IgG. During the follow-up period, 27.13% of symptomatic patients attended the ED, 11.83% were hospitalized and about 2% died. Results of the multivariate logistic regression analysis showed that the OR for a positive test was significantly increased in patients who had fever MESHD fever HP (>38{degrees}C), ageusia MESHD and contact with a patient diagnosed with COVID-19. Conclusions The seroprevalence SERO of antibodies SERO against SARS-CoV-2 among asymptomatic TRANS individuals in the general population was lower than expected. Approximately 40% of the symptomatic patients followed by GPs during the peak months of the pandemic in Barcelona, were positive. Fever MESHD Fever HP (>38{degrees}C), anosmia HP, ageusia MESHD and contact with a patient diagnosed with COVID-19 were associated with a positive test result.

    Possible COVID-19 recurrence MESHD in an older patient: a case report

    Authors: Antoine Garnier-Crussard; Marine Haution ; Mathilde Gueret-Du-Manoir ; Quitterie Reynaud ; Nathalie Freymond ; Maude Bouscambert-Duchamp ; Anne Conrad ; Claire Falandry

    doi:10.21203/ Date: 2020-06-11 Source: ResearchSquare

    Background: Novel coronavirus (COVID-19) pandemic cause by Severe Acute Respiratory Syndrome MESHD Coronavirus-2 (SARS-CoV-2) threatens the world for few months. Few cases of prolonged positivity of viral tests and clinical recurrence MESHD of COVID-19 have been described. We report the case of a 78-year-old woman with metastatic breast cancer who developed possible COVID-19 recurrence MESHD in a post-acute and rehabilitation unit. Case presentation: A 78-year-old woman with metastatic breast cancer and hypertension MESHD hypertension HP developed COVID-19. After symptom improvement and RT-PCR negativation, she regained symptom ( fever MESHD fever HP, fall HP) and lymphopenia MESHD lymphopenia HP on Day 26 and we note a turned positive RT-PCR even though she was tested positive for antibody SERO against SARS-CoV-2. After the diagnosis of possible COVID-19 recurrence MESHD, she was transferred back to an acute “COVID-19” unit and she then quickly clinically recovered. Conclusions: This clinical case allows us to discuss the risk of recurrence MESHD and possible specific causes in older patients. Moreover, prolonged symptoms and lymphopenia MESHD lymphopenia HP could be associated to worse outcomes in older patients. Finally, at a collective level, even if traces TRANS of virus detected by RT-PCR were not necessarily correlated with the contagiousness, the importance of possible COVID-19 recurrence MESHD in the care pathway for older adults TRANS must be taken into account, since they are often surrounded by frail older people.

    COVID-19 with Positive Bronchoalveolar Lavage Fluid (BALF) But Negative Nasopharyngeal and Oropharyngeal Swabs: Case Report and Insights

    Authors: Reza Jahromi; Arezoo Avazpour; Maryam Jahromi; Jalile Alavi

    id:10.20944/preprints202006.0113.v1 Date: 2020-06-09 Source:

    Coronavirus disease MESHD 2019 (COVID-19), caused by the severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2), mainly affects the respiratory system with some patients rapidly progressing to acute respiratory distress HP syndrome MESHD (ARDS). The most common symptoms of the patients are fever MESHD fever HP, cough MESHD cough HP, dyspnea MESHD dyspnea HP, myalgia MESHD myalgia HP, and fatigue MESHD fatigue HP. Nasopharyngeal and oropharyngeal swab specimens tested by real-time reverse transcription-polymerase chain reaction (RT-PCR) are the most commonly used methods to diagnose COVID-19. Herein, we investigate and discuss a young case of COVID-19, without any pre-existing medical conditions, whose both nasopharyngeal and oropharyngeal swab tests of SARS-CoV-2 were negative in the prodromal phase. However, after three days, with severe dyspnea MESHD dyspnea HP and rapidly progressed acute respiratory distress HP syndrome MESHD (ARDS), the case was identified as infected by COVID-19 by testing bronchoalveolar lavage fluid (BALF). The patient was intubated in the intensive care unit (ICU) but expired on the fourth day. This case shows the importance of active and accurate monitoring of the patients showing COVID-19 symptoms. Although the BALF test has a higher exposure risk, it is considered more accurate and recommended if performed by an expert operator.

    What is the clinical course of patients hospitalised for COVID-19 treatment Ireland: a retrospective cohort study in Dublin’s North Inner City (the ‘Mater 100’)

    Authors: Brendan O’Kelly* ; Colm Cronin* ; Stephen Peter Connolly*; Walter Cullen; Gordana Avramovic; Tina McHugh; Eileen O’Connor; Aoife Cotter; Peter Doran; Tara McGinty ; Dermot O’Callaghan; Sean Gaine ; Gerard Sheehan; Eamonn Brazil; Brian Marsh ; John S. Lambert

    doi:10.21203/ Date: 2020-06-08 Source: ResearchSquare

    Background: Since March 2020, Ireland has experienced an outbreak of coronavirus disease MESHD 2019 (COVID-19), caused by severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2). To date, while several cohorts from China have been described, our understanding is limited, with no data describing the epidemiological and clinical characteristics of patients with COVID-19 in Ireland. To improve our understanding of the clinical characteristics of this emerging infection MESHD we carried out a retrospective review of patient data to examine the clinical characteristics of patients admitted for COVID-19 hospital treatment.Methods: Demographic, clinical and laboratory data on the first 100 adult TRANS patients admitted to Mater Misericordiae University Hospital (MMUH) for in-patient COVID-19 treatment after onset of the outbreak in March 2020 was extracted from clinical and administrative records. Missing data were excluded from the analysis.Results: Fifty-eight per cent were male TRANS, 63% were Irish nationals, 29% were GMS eligible, and median age TRANS was 45 years (interquartile range [IQR] =34-64 years). Patients had symptoms for a median of five days before diagnosis (IQR=2.5-7 days), most commonly cough MESHD cough HP (72%), fever MESHD fever HP (65%), dyspnoea (37%), fatigue MESHD fatigue HP (28%), myalgia MESHD myalgia HP (27%) and headache MESHD headache HP (24%). Of all cases, 54 had at least one pre-existing chronic illness (most commonly hypertension MESHD hypertension HP, diabetes mellitus MESHD diabetes mellitus HP or asthma MESHD asthma HP). At initial assessment, the most common abnormal findings were: C-reactive protein >7.0mg/L (74%), ferritin >247μg/L (women) or >275μg/L (men) (62%), D-dimer >0.5μg/dL (62%), chest imaging (59%), NEWS Score (modified) of ≥3 (55%) and heart rate >90/min (51%). Twenty-seven required supplemental oxygen, of which 17 were admitted to the intensive care unit - 14 requiring ventilation. Forty received antiviral treatment (most commonly hydroxychloroquine or lopinavir/ritonavir). Four died, 17 were admitted to intensive care, and 74 were discharged home, with nine days the median hospital stay (IQR=6-11).Conclusion: Our findings reinforce the emerging consensus of COVID-19 as an acute life-threatening disease MESHD and highlights, the importance of laboratory (ferritin, C-reactive protein, D-dimer) and radiological parameters, in addition to clinical parameters. Further cohort studies involving larger samples followed longitudinally are a priority.

    A COVID-19 outbreak in a rheumatology department upon the early days of the pandemic

    Authors: Vasco C. Romão; Filipa Oliveira-Ramos; Ana Rita Cruz-Machado; Patrícia Martins; Sofia Barreira; Joana Silva-Dinis; Luís Galaio; Helena Proença; José Melo Cristino; Ema Sacadura-Leite; Nikita Khmelinskii; José Carlos Romeu; João Eurico Fonseca; - CHULN Rheumatology Department

    doi:10.1101/2020.06.05.20107011 Date: 2020-06-08 Source: medRxiv

    Objectives: To describe our experience with a coronavirus disease MESHD 2019 (COVID-19) outbreak within a large rheumatology department, early in the pandemic. Methods: Symptomatic and asymptomatic TRANS healthcare workers (HCWs) had a naso-oropharyngeal swab for detection of severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) and were followed clinically. Reverse transcription polymerase-chain reaction (RT-PCR) was repeated to document cure, and serological response was assessed. Patients with risk contacts within the department in the 14 days preceding the outbreak were screened for COVID-19 symptoms. Results: 14/34 HCWs (41%; 40{+/-}14 years, 71% female TRANS) tested positive for SARS-CoV-2, and 11/34 (32%) developed symptoms but were RT-PCR-negative. Half of RT-PCR-positive HCWs did not report fever MESHD fever HP, cough MESHD cough HP, or dyspnoea before testing, which were absent in 3/14 cases (21%). Mild disease MESHD prevailed (79%), but 3 HCWs had moderate disease MESHD requiring further assessment, which excluded severe complications. Nevertheless, symptom duration (28{+/-}18 days), viral shedding (31{+/-}10 days post- symptom onset TRANS, range 15-51) and work absence (29{+/-}28 days) were prolonged. 13/14 (93%) of RT-PCR-positive and none of the RT-PCR-negative HCWs had a positive humoral response, with higher IgG-index in individuals over 50 years (14.5{+/-}7.7 vs 5.0{+/-}4.4, p=0.012). Of 617 rheumatic patients, 8 (1.3%) developed COVID-19 symptoms (1/8 hospitalisation, 8/8 complete recovery), following a consultation/procedure with an asymptomatic TRANS (7/8) or mildly-symptomatic (1/8) HCW. Conclusions: A COVID-19 outbreak can occur among HCWs and rheumatic patients, swiftly spreading over the presymptomatic stage. Mild disease MESHD without typical symptoms should be recognised, and may evolve with delayed viral shedding, prolonged recovery, and adequate immune response in most individuals.


    Authors: Banu Uygun-Can; Bilge Acar-Bolat

    doi:10.1101/2020.06.06.20123901 Date: 2020-06-07 Source: medRxiv

    We aimed to summarize reliable medical evidence by the meta-analysis of all published retrospective studies that examined data based on the detection of severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) by clinical symptoms, molecular (RT-PCR) diagnosis and characteristic CT imaging features in pregnant women. MEDLINE PubMed, SCOPUS, ISI Web of Science, Clinical Key, and CINAHL databases were used to select the studies. Then, 384 articles were received, including the studies until 01/MAY/2020. As a result of the full-text evaluation, 12 retrospective articles covering all the data related were selected. A total of 181 pregnant cases with SARS-CoV-2 infections MESHD were included in the meta-analysis within the scope of these articles. According to the results, the incidence of fever MESHD fever HP was 38.1% (95% CI: 14.2-65%), and cough MESHD cough HP was 22% (95% CI: 10.8-35.2%) among all clinical features of pregnant cases with SARS-CoV-2 infection MESHD. So, fever MESHD fever HP and cough MESHD cough HP are the most common symptoms in pregnant cases with SARS-CoV-2 infection MESHD, and 91.8% (95% CI: 76.7-99.9%) of RT-PCR results are positive. Moreover, abnormal CT incidence is 97.9% (95% CI: 94.2-99.9%) positive. No case was death MESHD. However, as this virus spreads globally, it should not be overlooked that the incidence will increase in pregnant women and may be in the risky group. RT-PCR and CT can be used together in an accurate and safe diagnosis. In conclusion, these findings will provide important guidance for current studies regarding the clinical features and correct detection of SARS-CoV-2 infection MESHD in pregnant women, as well as whether it will create emergency MESHD tables that will require the use of a viral drug.

    Olfactory transmucosal SARS-CoV-2 invasion as port of Central Nervous System entry in COVID-19 patients

    Authors: Jenny Meinhardt; Josefine Radke; Carsten Dittmayer; Ronja Mothes; Jonas Franz; Michael Laue; Julia Schneider; Sebastian Bruenink; Olga Hassan; Werner Stenzel; Marc Windgassen; ; Larissa Roessler; Hans-Hilmar Goebel; Hubert Martin; Andreas Nitsche; Walter Schulz-Schaeffer; Samy Hakroush; Martin S Winkler; Bjoern Tampe; Sefer Elezkurtaj; David Horst; Lars Oesterhelweg; Michael Tsokos; Barbara Ingold Heppner; Christine Stadelmann; Christian Drosten; Victor M Corman; Helena Radbruch; Frank L Heppner

    doi:10.1101/2020.06.04.135012 Date: 2020-06-04 Source: bioRxiv

    The newly identified severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) causes COVID-19, a pandemic respiratory disease MESHD presenting with fever MESHD fever HP, cough MESHD cough HP, and often pneumonia MESHD pneumonia HP. Moreover, thromboembolic events throughout the body including the central nervous system (CNS) have been described. Given first indication for viral RNA presence in the brain and cerebrospinal fluid and in light of neurological symptoms in a large majority of COVID-19 patients, SARS-CoV-2-penetrance of the CNS is likely. By precisely investigating and anatomically mapping oro- and pharyngeal regions and brains of 32 patients dying from COVID-19, we not only describe CNS infarction due to cerebral MESHD thromboembolism MESHD thromboembolism HP, but also demonstrate SARS-CoV-2 neurotropism. SARS-CoV-2 enters the nervous system via trespassing the neuro-mucosal interface in the olfactory mucosa by exploiting the close vicinity of olfactory mucosal and nervous tissue including delicate olfactory and sensitive nerve endings. Subsequently, SARS-CoV-2 follows defined neuroanatomical structures, penetrating defined neuroanatomical areas, including the primary respiratory and cardiovascular control center in the medulla oblongata.

    CT features of pneumonia MESHD pneumonia HP during COVID-19 pandemic warrant caution: An illustrative case report of cholangiocarcinoma MESHD cholangiocarcinoma HP with Pneumocystis jiroveci pneumonia MESHD pneumonia HP

    Authors: Fang Liu; Wen Li

    doi:10.21203/ Date: 2020-06-02 Source: ResearchSquare

    Background: An outbreak of severe acute respiratory syndrome MESHD due to coronavirus 2 (SARS-CoV-2) infection MESHD (COVID-19) that began at Wuhan, China in December 2019, spreading rapidly across China and many other countries. Considering the high false-negative rate of RT-PCR assay during initial COVID-19 pandemic in China, chest computed tomography (CT) was advocated as a means of corroborating clinically suspected infections MESHD.Case presentation: A 51-year-old man with clinical diagnosis of hepatic portal cholangiocarcinoma MESHD cholangiocarcinoma HP and Behcet's disease MESHD developed clinical manifestations suggestive of COVID-19 during the pandemic in China. The chest CT showed rapid progression to diffuse ground-glass opacities (GCOs) in both lungs, as in severe cases of confirmed TRANS COVID-19. He was finally diagnosed with Pneumocystis jiroveci pneumonia MESHD pneumonia HP (PJP) according to the medical history, and Caspofungin plus TMP/SMX elicited a rapid response as normalizing both temperature and leukocyte count initially. Unfortunately, dyspnea MESHD dyspnea HP was aggravated with resumed fever MESHD fever HP later, and non-invasive ventilation was no longer tenable. The patient himself (with support of his family) declined mechanical ventilatory assistance, succumbing to pneumonia MESHD pneumonia HP and respiratory failure HP finally.Conclusions: CT diagnosis of COVID-19 during the current pandemic should warrant caution.

    Screening and Analysis of COVID-19 cases in non-epidemic areas: A Retrospective Study

    Authors: Yan Zhu; Yan Guo; Juan Ma; Mao-shi Li; Jia-fei Chen; Ming Liu; Ze-hui Yan; Guo-hong Deng; Qing Mao; Hui-min Liu

    doi:10.21203/ Date: 2020-06-01 Source: ResearchSquare

    Objective: To compare the epidemiological and clinical characteristics of confirmed and suspected corona virus disease MESHD 2019 (COVID-19) cases via the process of “triage-screening-isolation-transfer” in the hospitals of non-epidemic areas.Methods: The general data, epidemiological history, clinical symptoms, laboratory examination, and chest computed tomography (CT) imaging characteristics of 38 patients with suspected COVID-19, admitted between January 21 and March 5, 2020, were analyzed.Results: According to the results of the novel severe acute respiratory syndrome MESHD coronavirus (SARS-CoV-2) ribonucleic acid (RNA) testing, the patients were divided into study group (RNA positive) and control group (RNA negative). Ultimately, 8 cases were RNA-positive and diagnosed as CDVID-19, and 30 cases were negative. Approximately half of the patients in the study group returned to Chongqing from Wuhan; this number was significantly larger than that of the control group (P<0.05). The number of subjects in close contact TRANS with the confirmed cases TRANS with SARS-CoV-2 RNA-positive and the incidence of aggregation was significantly larger in the study group than in the control group (both P<0.05). The clinical symptom of the study group was mainly low fever MESHD fever HP (with or without cough MESHD cough HP). The patients with decreased white blood SERO cells (WBC) in the study group were significantly more than those in the control group (P<0.05). Both group had reduced lymphocytes (Lym) but the number of patients with increased C-reactive protein (CRP) in the study group was significantly more than that in the control group (P<0.05). There were different degrees of chest CT abnormalities in both study and control group (P > 0.05). Conclusion: The epidemiological investigations in screening for infectious diseases MESHD is crucial. The risk of infection TRANS risk of infection TRANS infection MESHD was high from the primary epidemic area and/or in close contact TRANS with the confirmed case TRANS. The most common form of clustering occurrence was family aggregation. CDVID-19 was mainly characterized by fever MESHD fever HP and respiratory symptoms, although asymptomatic infection MESHD asymptomatic TRANS may also occur. Decreased WBC, decreased Lym, and increased CRP are common characteristics but can also be combined with other respiratory tract virus infections MESHD. COVID 19 screening by chest CT alone had certain limitations in non- epidemic areas.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.